Phase II trial of 13-cis-retinoic acid in metastatic breast cancer

Jane Cassidy, Marc E Lippman, Andre Lacroix, Gary Peck

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Studies have suggested that both natural and synthetic retinoids have extensive chemopreventive activity against a variety of carcinogens in vivo and in vitro. We have previously shown that growth of human breast cancer cells can be inhibited by retinoids, and retinoic acid-binding proteins have been demonstrated in these cell lines and tumor biopsies. We studied the activity of 13-cis-retinoic acid in the treatment of 18 patients with advanced breast cancer refractory to standard cytotoxic and/or endocrine therapy. Patients began on 0.5 mg/kg and escalated to 8 mg/kg over a one-month period unless toxicity (dry skin, dry mucosa, cheilitis, conjunctivitis) forced dose reduction. All these toxicities responded promptly to dose reduction. Four patients exhibited drug related hypercalcemia, 2 complained of severe earache and several had nausea, vomiting and abdominal cramping. There were no objective responses as defined by standard criteria. One patient with thrombocytopenia secondary to documented marrow involvement demonstrated a recovery of platelet count from 9000 to 110,000. 13-cis-Retinoic acid is not of apparent value in women with heavily pretreated breast cancer.

Original languageEnglish
Pages (from-to)925-928
Number of pages4
JournalEuropean Journal of Cancer and Clinical Oncology
Volume18
Issue number10
DOIs
StatePublished - Jan 1 1982
Externally publishedYes

Fingerprint

Isotretinoin
Breast Neoplasms
Retinoids
Cheilitis
Earache
Retinoic Acid Receptors
Conjunctivitis
Hypercalcemia
Tumor Cell Line
Platelet Count
Thrombocytopenia
Carcinogens
Nausea
Vomiting
Mucous Membrane
Bone Marrow
Biopsy
Skin
Therapeutics
Growth

ASJC Scopus subject areas

  • Oncology

Cite this

Phase II trial of 13-cis-retinoic acid in metastatic breast cancer. / Cassidy, Jane; Lippman, Marc E; Lacroix, Andre; Peck, Gary.

In: European Journal of Cancer and Clinical Oncology, Vol. 18, No. 10, 01.01.1982, p. 925-928.

Research output: Contribution to journalArticle

Cassidy, Jane ; Lippman, Marc E ; Lacroix, Andre ; Peck, Gary. / Phase II trial of 13-cis-retinoic acid in metastatic breast cancer. In: European Journal of Cancer and Clinical Oncology. 1982 ; Vol. 18, No. 10. pp. 925-928.
@article{3e6304cb056c4f129b04b8018596bf4a,
title = "Phase II trial of 13-cis-retinoic acid in metastatic breast cancer",
abstract = "Studies have suggested that both natural and synthetic retinoids have extensive chemopreventive activity against a variety of carcinogens in vivo and in vitro. We have previously shown that growth of human breast cancer cells can be inhibited by retinoids, and retinoic acid-binding proteins have been demonstrated in these cell lines and tumor biopsies. We studied the activity of 13-cis-retinoic acid in the treatment of 18 patients with advanced breast cancer refractory to standard cytotoxic and/or endocrine therapy. Patients began on 0.5 mg/kg and escalated to 8 mg/kg over a one-month period unless toxicity (dry skin, dry mucosa, cheilitis, conjunctivitis) forced dose reduction. All these toxicities responded promptly to dose reduction. Four patients exhibited drug related hypercalcemia, 2 complained of severe earache and several had nausea, vomiting and abdominal cramping. There were no objective responses as defined by standard criteria. One patient with thrombocytopenia secondary to documented marrow involvement demonstrated a recovery of platelet count from 9000 to 110,000. 13-cis-Retinoic acid is not of apparent value in women with heavily pretreated breast cancer.",
author = "Jane Cassidy and Lippman, {Marc E} and Andre Lacroix and Gary Peck",
year = "1982",
month = "1",
day = "1",
doi = "10.1016/0277-5379(82)90239-5",
language = "English",
volume = "18",
pages = "925--928",
journal = "European Journal of Cancer and Clinical Oncology",
issn = "0277-5379",
publisher = "Pergamon Press",
number = "10",

}

TY - JOUR

T1 - Phase II trial of 13-cis-retinoic acid in metastatic breast cancer

AU - Cassidy, Jane

AU - Lippman, Marc E

AU - Lacroix, Andre

AU - Peck, Gary

PY - 1982/1/1

Y1 - 1982/1/1

N2 - Studies have suggested that both natural and synthetic retinoids have extensive chemopreventive activity against a variety of carcinogens in vivo and in vitro. We have previously shown that growth of human breast cancer cells can be inhibited by retinoids, and retinoic acid-binding proteins have been demonstrated in these cell lines and tumor biopsies. We studied the activity of 13-cis-retinoic acid in the treatment of 18 patients with advanced breast cancer refractory to standard cytotoxic and/or endocrine therapy. Patients began on 0.5 mg/kg and escalated to 8 mg/kg over a one-month period unless toxicity (dry skin, dry mucosa, cheilitis, conjunctivitis) forced dose reduction. All these toxicities responded promptly to dose reduction. Four patients exhibited drug related hypercalcemia, 2 complained of severe earache and several had nausea, vomiting and abdominal cramping. There were no objective responses as defined by standard criteria. One patient with thrombocytopenia secondary to documented marrow involvement demonstrated a recovery of platelet count from 9000 to 110,000. 13-cis-Retinoic acid is not of apparent value in women with heavily pretreated breast cancer.

AB - Studies have suggested that both natural and synthetic retinoids have extensive chemopreventive activity against a variety of carcinogens in vivo and in vitro. We have previously shown that growth of human breast cancer cells can be inhibited by retinoids, and retinoic acid-binding proteins have been demonstrated in these cell lines and tumor biopsies. We studied the activity of 13-cis-retinoic acid in the treatment of 18 patients with advanced breast cancer refractory to standard cytotoxic and/or endocrine therapy. Patients began on 0.5 mg/kg and escalated to 8 mg/kg over a one-month period unless toxicity (dry skin, dry mucosa, cheilitis, conjunctivitis) forced dose reduction. All these toxicities responded promptly to dose reduction. Four patients exhibited drug related hypercalcemia, 2 complained of severe earache and several had nausea, vomiting and abdominal cramping. There were no objective responses as defined by standard criteria. One patient with thrombocytopenia secondary to documented marrow involvement demonstrated a recovery of platelet count from 9000 to 110,000. 13-cis-Retinoic acid is not of apparent value in women with heavily pretreated breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0020352922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020352922&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(82)90239-5

DO - 10.1016/0277-5379(82)90239-5

M3 - Article

C2 - 6962067

AN - SCOPUS:0020352922

VL - 18

SP - 925

EP - 928

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

SN - 0277-5379

IS - 10

ER -